EGFR and cancer: Similarly, KRAS mutations, particularly the pathogenic c.35G>T (p.Gly12Val) variant identified in this study, are well-known drivers of cancer and are associated with resistance to certain therapies, such as anti-EGFR monoclonal antibodies.